The problem of helicobacter pylori resistance to antibiotics: A systematic review in latin America

American Journal of Gastroenterology

Volumn 109, Issue 4, 2014, Pages 485-495

  Camargo, M Constanza ^a   García, Apolinaria ^b   Riquelme, Arnoldo ^c   Otero, William ^d,e   Camargo, Claudia A ^f   Hernandez García, Tomas ^b   Candia, Roberto ^c   Bruce, Michael G ^g   Rabkin, Charles S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CONCEPCIÓN   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^e Unidad de Gastroenterología Clínica Fundadores   (Colombia)

^f SECRETARÍA DE SALUD   (Mexico)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FURAZOLIDONE; METRONIDAZOLE; QUINOLONE DERIVATIVE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM ISOLATE; CENTRAL AMERICA; DISEASE ASSOCIATION; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOUTH AMERICA; STOMACH CANCER; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LATIN AMERICA; MODELS, STATISTICAL;

EID: 84898016784     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.24     Document Type: Review

References (45)

1. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risks to humans: Schistosomes, liver flukes and Helicobacter pylori. 1st edn. IARC Press: Lyon, France, 1994.
2. Ford AC, Delaney BC, Forman D et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006; (2): CD003840.
3. Zullo A, Hassan C, Cristofari F et al. effects of Helicobacter pylori eradication on early stage gastric mucosa-Associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010; 8: 105-10.
4. Ma JL, Zhang L, Brown LM et al. Fift een-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012; 104: 488-92.
5. Fischbach L, Evans EL. Meta-Analysis: The effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-57.
6. McMahon BJ, Hennessy TW, Bensler JM et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139: 463-9.
7. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-The Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
8. Coelho LG, Leon-Barua R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affi liated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol 2000; 95: 2688-91.
9. Parkin DM. The global health burden of infection-Associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-44.
10. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10, In: International Agency for Research on Cancer (ed). Lyon: France, 2010.
11. Wolff MJ. Use and misuse of antibiotics in Latin-America. Clin Infect Dis 1993; 17: S346-51.
12. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. BMJ 2009; 339: B2535.
13. UNESCO The State of Education in Latin America and the Caribbean Guaranteeing Quality Education for All 2008.
14. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
15. Freeman MF, Tukey JW. Transformations related to the angular and the square root. Annals Math Stat 1950; 21: 607-11.
16. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in metaanalyses. BMJ 2003; 327: 557-60.
17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
18. Egger M, Davey Smith G, Schneider M et al. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
19. Sterne JAC. Meta-Analysis in Stata: An Updated Collection from the Stata Journal. Stata Press: College Station, TX, USA, 2009.
20. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
21. You WC, Brown LM, Zhang L et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 974-83.
22. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53.
23. Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 2004; 64: 1893-904.
24. Kuo CH, Kuo FC, Hu HM et al. The optimal first-line therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract 2012; 2012: 168361.
25. Megraud F, Coenen S, Versporten A et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
26. De Francesco V, Giorgio F, Hassan C et al. Worldwide H. pylori antibiotic resistance: A systematic review. J Gastrointestin Liver Dis 2010; 19: 409-14.
27. Gao W, Cheng H, Hu F et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010; 15: 460-6.
28. Kobayashi I, Murakami K, Kato M et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007; 45: 4006-10.
29. Andrade SS, Sader HS, Jones RN et al. Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: Time for local guidelines?. Mem Inst Oswaldo Cruz 2006; 101: 741-8.
30. Hirschl AM, Hirschl MM, Rotter ML. Comparison of three methods for the determination of the sensitivity of Helicobacter pylori to metronidazole. J Antimicrob Chemother 1993; 32: 45-9.
31. Glupczynski Y, Broutet N, Cantagrel A et al. Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002; 21: 549-52.
32. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322.
33. Malfertheiner P, Bazzoli F, Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-13.
34. Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 2010; 8: 59-70.
35. Wirtz VJ, Dreser A, Gonzales R. Trends in antibiotic utilization in eight Latin American countries, 1997-2007. Rev Panam Salud Publica 2010; 27: 219-25.
36. Tveit AH, Bruce MG, Bruden DL et al. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol 2011; 49: 3638-43.
37. Khan A, Farooqui A, Manzoor H et al. Antibiotic resistance and cagA gene correlation: A looming crisis of Helicobacter pylori. World J Gastroenterol 2012; 18: 2245-52.
38. Correa P, van Doorn LJ, Bravo JC et al. Unsuccessful treatment results in survival of less virulent genotypes of Helicobacter pylori in Colombian patients. Am J Gastroenterol 2000; 95: 564-6.
39. Suzuki T, Matsuo K, Sawaki A et al. Systematic review and meta-Analysis: Importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 24: 273-80.
40. Piccolomini R, DiBonaventura G, Catamo G et al. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J Clin Microbiol 1997; 35: 1842-6.
41. Suzuki T, Matsuo K, Ito H et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006; 119: 217-24.
42. Al-Eidan FA, McElnay JC, Scott MG et al. Management of Helicobacter pylori eradication-The influence of structured counselling and follow-up. Br J Clin Pharmacol 2002; 53: 163-71.
43. Zullo A, De Francesco V, Hassan C. Predicting Helicobacter pylori eradication: How to teach an old dog new tricks!. J Clin Gastroenterol 2012; 46: 259-61.
44. Isaza C, Henao J, Martinez JH et al. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Clin Pharmacol 2007; 7: 6-10.
45. Bravo-Villalta HV, Yamamoto K, Nakamura K et al. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: An investigative and comparative study. Eur J Clin Pharmacol 2005; 61: 179-84.